Format

Send to

Choose Destination
Breast Cancer Res Treat. 2012 Oct;135(3):867-73. doi: 10.1007/s10549-012-2214-2. Epub 2012 Aug 23.

Is the prevalence of ER-negative breast cancer in the US higher among Africa-born than US-born black women?

Author information

1
Surveillance Research, American Cancer Society, 250 Williams Street, NW, Atlanta, GA 30303-1002, USA. ahmedin.jemal@cancer.org

Abstract

Previous studies have reported that the prevalence of ER-negative tumors in breast cancer patients is much higher in black women than in white women in the US. Herein, we examine whether the proportion (prevalence) in Africa-born black breast cancer patients residing in the US is similar to those in US-born black patients. We obtained information on invasive female breast cancers diagnosed during 1996-2008 in 17 Surveillance Epidemiology and End Results cancer registries according to select place of birth: Western-Africa-born, Eastern-Africa-born, Jamaica-born, and US-born blacks and US-born whites. The majority of Western-Africa-born and Eastern-Africa-born blacks were from Nigeria (64 %) and Ethiopia (74 %), respectively. We examined group variations in ER status using Chi-squared tests and the prevalence of ER-negative tumors in Africa-born blacks compared to US-born blacks, expressed as prevalence ratio (PRR), using multivariable regression models. The prevalence of ER-negative tumors significantly varied from 22.0 % (n = 41/186) in Eastern-Africa-born to 32.9 % (n = 47/143) in Western-Africa-born blacks. After adjustment for differences in age at diagnosis and other covariates, compared to US-born blacks, the prevalence was similar in Western-Africa-born (PRR = 0.87; 95 % CI 0.70-1.08) and Jamaica-born blacks (PRR = 0.88; 95 % CI 0.74-1.03), but significantly lower in Eastern-Africa-born blacks (PRR = 0.58; 95 % CI 0.44-0.75). Notably, the ER-negative prevalence in Eastern-Africa-born black was comparable to the US-born whites with breast cancer. Our findings highlight the heterogeneity of breast cancer among black women in the US, which should be considered in future studies of hormone receptor status in these women.

PMID:
22915073
DOI:
10.1007/s10549-012-2214-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center